Robeco Institutional Asset Management B.V. raised its stake in Mylan NV (NASDAQ:MYL) by 63.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 262,758 shares of the company’s stock after buying an additional 101,541 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Mylan were worth $7,446,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Teachers Advisors LLC raised its stake in Mylan by 1.0% in the third quarter. Teachers Advisors LLC now owns 2,099,625 shares of the company’s stock worth $76,846,000 after buying an additional 21,416 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Mylan by 8.6% during the third quarter. Legal & General Group Plc now owns 2,693,774 shares of the company’s stock valued at $98,592,000 after purchasing an additional 212,529 shares in the last quarter. Vanguard Group Inc increased its stake in shares of Mylan by 1.4% during the third quarter. Vanguard Group Inc now owns 35,774,112 shares of the company’s stock valued at $1,309,333,000 after purchasing an additional 506,649 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Mylan by 5.7% during the fourth quarter. State of Alaska Department of Revenue now owns 78,359 shares of the company’s stock valued at $2,146,000 after purchasing an additional 4,224 shares in the last quarter. Finally, First Hawaiian Bank increased its stake in shares of Mylan by 560.4% during the fourth quarter. First Hawaiian Bank now owns 2,886 shares of the company’s stock valued at $79,000 after purchasing an additional 2,449 shares in the last quarter. 83.69% of the stock is owned by institutional investors.

In related news, insider Paul Campbell sold 11,533 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $27.50, for a total value of $317,157.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.81% of the company’s stock.

Shares of MYL opened at $20.41 on Thursday. The company has a market cap of $10.35 billion, a P/E ratio of 4.46, a PEG ratio of 1.04 and a beta of 1.44. The company has a quick ratio of 0.85, a current ratio of 1.51 and a debt-to-equity ratio of 1.20. Mylan NV has a twelve month low of $19.40 and a twelve month high of $42.50.

Mylan (NASDAQ:MYL) last issued its earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.03. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The company had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.70 billion. During the same quarter last year, the company posted $0.96 earnings per share. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Mylan NV will post 4.28 EPS for the current fiscal year.

A number of equities analysts have weighed in on MYL shares. Zacks Investment Research raised shares of Mylan from a “hold” rating to a “strong-buy” rating and set a $34.00 target price for the company in a research note on Monday, January 21st. UBS Group downgraded shares of Mylan from a “buy” rating to a “neutral” rating and decreased their target price for the company from $54.00 to $32.00 in a research note on Wednesday, January 23rd. Credit Suisse Group reissued a “buy” rating and set a $37.00 price target on shares of Mylan in a research report on Wednesday, March 6th. Morgan Stanley raised shares of Mylan from an “equal weight” rating to an “overweight” rating and set a $35.00 price target for the company in a research report on Wednesday, March 6th. They noted that the move was a valuation call. Finally, SunTrust Banks started coverage on shares of Mylan in a research report on Tuesday, March 19th. They set a “buy” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $37.35.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2019/05/16/robeco-institutional-asset-management-b-v-grows-holdings-in-mylan-nv-myl.html.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Read More: What is a blue-chip stock?

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.